Bedaquiline Fumarate

富马酸贝达喹啉

Report date: 2026/05/13 20:02:10
NMEFirst In Class

Base Information

Drug NameBedaquiline Fumarate
Drug Alias NameBedaquilinaBedaquilinum斯耐瑞Sirturo
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics
Mechanisms of ActionATP synthase inhibitors
TargetsATP synthase
Therapy Area/IndicationsMultidrug-Resistant InfectionHIV InfectionsTuberculosis, Multidrug-Resistant +[6] 
Global Approved IndicationsTuberculosis, Multidrug-Resistant
Approved Indications in ChinaTuberculosis, Multidrug-Resistant
Original Approved Country/TerritoryUnited States
Original Approved Date2012/12/28
Country/TerritoryUnited StatesUkraineTaiwan +[29] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJohnson & Johnson Innovative MedicineJohnson & Johnson
China Registration ClassN/A

Develop Information

Active CompaniesJohnson & Johnson Innovative MedicineJanssen-Cilag International NvJanssen Therap +[8] 
Inactive CompaniesEunice Kennedy Shriver National Institute Of Child Health And Human DevelopmentTibotec BvbaNational Institute Of Mental Health (Nimh) +[4] 
Active IndicationsMultidrug-Resistant InfectionHIV InfectionsTuberculosis, Multidrug-Resistant +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeJ04AK05
Related LinksWikipediaDrugBankKEGG